unstable angina undergoing PCI.

JPAD The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial. Efficacy of Low-Dose Aspirin Therapy for the Primary Prevention.
Prévention de la mortalité de l’IDM aigu
PEACE* Prévention par un IEC** (trandolapril) des accidents évolutifs graves chez des coronariens stables à fonction systolique ventriculaire gauche conservée.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
Apixaban versus warfarin in patients with atrial fibrillation
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
ISAR-REACT Anti-GPIIbIIIa (abciximab) en complément d’une dose de charge en clopidogrel avant angioplastie avec mise en place d’une endoprothèse coronaire.
TRA-CER Vorapaxar, a platelet thrombin receptor antagonist, in acute coronary syndromes. Mahaffey KW et al . AHA 2011.
un infarctus du myocarde récent.
Platelet inhibition with cangrelor in patients undergoing PCI.
ROCKET AF Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in Atrial.
Critère principal : décès CV, IDM ou AVC n = Médiane de suivi 33 mois
Bras standard (A) Hématocrite < 45 %
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:
Intravenous platelet blockade with cangrelor during PCI.
TRITON-TIMI 38 Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infraction.
AVERROES Apixaban versus acetylsalicylic acid (ASA) to reduce the risk of stroke Connolly S et al. ESC 2010.
AIDA STEMI The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Thiele H et al. AHA 2011.
Statines en prévention primaire  Quelles données et quels enjeux chez les personnes de plus de 75 ans ? Jean-Philippe Joseph et Fabrice Bonnet.
Prasugrel vs Clopidogrel for Patients managed with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography : a secondary,
CRASH-2 Effets de l’acide tranexamique sur la mortalité, les événements cardiovasculaires et la transfusion sanguine chez les patients traumatisés ayant.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack CHANCE Wang Y et al. N Engl J Med 2013 ;369:11-19.
WOMEN’s HEALTH STUDY (WHS) Effet de l’aspirine à faible dose pour la prévention du thromboembolisme veineux. Essai randomisé. Glynn RJ et al. Ann Intern.
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban once daily, oral,
CHARISMA Analyse post-hoc Complications hémorragiques de l’association clopidogrel + aspirine chez les patients avec maladie vasculaire stable ou avec.
ESPRIT Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT) : randomised controlled trial The ESPRIT Study.
PROTECT AF Fermeture percutanée de l’auricule gauche versus warfarine en prévention des AVC chez des patients en fibrillation auriculaire : étude randomisée.
LODOCO Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease Nidorf M et al. AHA 2012.
Cerebrovascular events in patients with atrial fibrillation randomized to edoxaban versus warfarin : effective anticoagulation with factor Xa next.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
FAME 2 Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease De Bruyne B et al. ESC 2012.
CHARISMA Clopidogrel + aspirine contre aspirine seule pour la prévention des accidents athérothrombotiques. Bhatt DL et al. N Engl J Med 2006;354:
Aspirin in Patients Undergoing Non Cardiac Surgery POISE 2 Devereaux PJ et al. NEJM 2014;370:
ARISTOTLE Apixaban versus warfarine dans la fibrillation atriale
POISE-2 Aspirin in patients undergoing noncardiac surgery ACC Devereaux P.J, et al. N Engl J Med 2014 ; 370 :
ACTIVE A Prévention des événements de la fibrillation auriculaire par le clopidogrel Effect of Clopidogrel added to Aspirin in patients with Atrial Fibrillation.
Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with non-valvular atrial fibrillation.
Prasugrel vs Clopidogrel for Acute Coronary Syndromes without Revascularization TRILOGY ACS Roe MT et al. N Engl J Med 2012 ; 367:
Edoxaban versus warfarin in patients with atrial fibrillation. ENGAGE-AF TIMI 48 Giugliano RP, et al. N Engl J Med 2013 ; 369 :
ASPIRE Low-dose Aspirin for Preventing Recurrent Venous Thromboembolism N Engl J Med 2012 DOI : /NEJMoa Brighton TA et al. AHA 2012.
La Lettre du Cancérologue Critères d’efficacité Co-primaires : SG SSP radiographique Secondaires : temps jusqu’à Progression de la douleur Progression.
RE-MODEL Study Essai clinique randomisé comparant
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
X-VERT Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with non-valvular atrial.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
THE CANAL COHORT STUDY Facteurs de risque de développement d’inhibiteur liés au traitement chez des patients naïfs atteints d’hémophilie A. Treatment-related.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
ADVANCE-3 Apixaban versus enoxaparin for thromboprophylaxis after hip replacement Lassen MR et al NEJM 2010; 363 :
Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
Phase 3 long acting rFIX glycoPEG Hémophilie B
ATLAS ACS 2 – TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome Gibson CM.
1–Thrombolysis in myocardial infarction
ATLANTIC Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery Montalescot.
IST-3 The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international.
CALISTO Fondaparinux pour le traitement
ATLAS ACS-TIMI 46 Rivaroxaban versus placebo dans le SCA
Surveillance AVK Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios.
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
ACCOAST Pretreatment with prasugrel in non-ST elevation acute coronary syndromes ESC 2013 Montalescot G, et al. N Engl J Med 2013.
AMADEUS Comparaison de l’idraparinux avec les AVK en prévention des accidents thrombo-emboliques de la fibrillation auriculaire : étude randomisée, ouverte,
HOKUSAI-VTE Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism ESC 2013 Büller HR et al. N Engl J Med 2013 ; 369 :
Marie Larouche, R1 UMF de Trois-Rivières
Platelet inhibition and patient outcomes
Strategies for Multivessel Revascularization in Patients with Diabetes
TRA 2° P Vorapaxar in the secondary prevention in atherothrombotic events Morrow DA et al. N Engl J Med 2012 ; 366 : Morrow DA et al. ACC 2012.
Étude ASCEND : AAS 100 mg/jour chez diabétiques sans maladie cardio-vasculaire à l’inclusion (1) Réalisée au Royaume-Uni 63 ans d’âge moyen, 63.
Host-ASSURE Adjunctive Cilostazol vs double dose clopidogrel after PCI with drug eluting stent Hyo-Soo K et al. ACC 2012.
TRILOGY ACS Prasugrel vs Clopidogrel for Acute Coronary Syndromes Patients managed without Revascularization. Ohman M, et al. ESC 2012.